Paul Hays
Board Member
President & CEO of Med-Pharmex, Inc., a developer, manufacturer, and distributor of veterinary drugs for companion animals and livestock located in Pomona, California. Mr. Hays has devoted his entire career, over 30 years, to the animal health industry.
Prior to joining Med-Pharmex, Mr. Hays was President & CEO for Virbac’s North American business, leading the acquisition of SENTINEL® brand parasiticide, strengthening the commercial organization and leading the turnaround of their FDA production facilities. He has also served as Chief Commercial Officer of Vets Plus and Vice President of Global Diagnostics at Pfizer Animal Health (today, Zoetis) where he led their entry into veterinary diagnostics through the integration of Synbiotics Corporation into Pfizer’s global business. Hays was Synbiotics’ President & CEO for eight years, first as a public company, which he took private and finally planned and led the sale to Pfizer.
Preceding those roles, Hays held progressive senior management roles with Boehringer Ingelheim Vetmedica including VP of Sales & Marketing where he founded both their equine and swine business units. The swine business unit grew rapidly under his leadership with the launch of the first PRRS and Ileitis vaccines and through the acquisitions of Fermenta Animal Health and NOBL Laboratories. Subsequently, he worked in Germany headquarters as Corporate VP of Marketing & Area Businesses, then returned to lead the US business as Executive Vice President of U.S. Business Operations. Earlier in his career, he was part of the US start-up team for CIBA Animal Health (later, Novartis) and began his career as sales representative for Coopers Animal Health. He earned a bachelor’s degree in animal science from the University of Missouri.